Home » Newsletters » BioWorld Science

BioWorld Science

June 20, 2017

View Archived Issues

Novel pocket-modified vancomycin analogues show potential as durable and potent antibiotics

Mutations in SCN9A gene linked to diabetic neuropathic pain

FDA accepts Rigel Pharmaceuticals' NDA for fostamatinib disodium

Axovant Sciences' nelotanserin obtains FDA fast track designation

Seattle Genetics halting phase III CASCADE study of vadastuximab talirine

Human umbilical cord mesenchymal stem cells evaluated in ischemic cardiomyopathy trial

EC approves biosimilar rituximab from Sandoz

Next generation diarylquinoline TBAJ-587 displays superior potency against tuberculosis

MedImmune introduces a novel anti-FcRII-a antibody

Engineered grafts show esophageal regeneration ability in a large animal model

Tessa Therapeutics enters alliance with Parker Institute for Cancer Immunotherapy

Cell Medica acquires Catapult Therapy TCR

Abide Therapeutics describes novel MGL/FAAH inhibitors

FDA approves Baxdela for ABSSSI

eFFECTOR Therapeutics identifies new MAP kinase signal-integrating kinase 1/2 inhibitors

Novel USP1 inhibitors identified at FORMA Therapeutics

Clovis Oncology presents positive topline data from phase III ARIEL3 study of rucaparib

ViiV Healthcare presents novel anti-HIV compounds

AstraZeneca, Cancer Research Technology patent GLS inhibitors

Narurapid and Narusus launched in Japan

Enzychem Lifesciences begins phase II trial of EC-18 in CIN

Novartis reports phase III data on RTH-258 in neovascular AMD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...